Safety, immunogenicity, persistence and dose evaluation of the CS-2034 mRNA COVID-19 vaccine: a phase II randomized controlled trial in healthy Chinese adults
The study was registered at ClinicalTrials.gov under the identifier NCT05373472 (registration date: May 13, 2022).
Authors
- Xiaofang Wu (ORCID: https://orcid.org/0000-0002-3782-7701)
- Jingxuan Wu (ORCID: https://orcid.org/0000-0002-3128-7601)
- Hang Hubert Yin (ORCID: https://orcid.org/0000-0002-9762-4818)
- Ruihua Dong (ORCID: https://orcid.org/0000-0003-3463-5023)
- Jun Liu (ORCID: https://orcid.org/0000-0001-9021-4632)
- Haomeng Wang
- Jin-Bo Gou
- Baoying Huang (ORCID: https://orcid.org/0000-0001-9516-1146)
- Tao Zhu (ORCID: https://orcid.org/0000-0003-4197-0065)
- Tao Huang (ORCID: https://orcid.org/0009-0004-5138-6078)
- Jin Li (ORCID: https://orcid.org/0000-0001-9201-2321)
- Jian Liu (ORCID: https://orcid.org/0000-0002-1825-571X)
- Kexin Zhao (ORCID: https://orcid.org/0009-0003-0661-0889)
- Meijuan Zhang (ORCID: https://orcid.org/0000-0003-1208-8225)
- Jian Song (ORCID: https://orcid.org/0000-0002-2459-7046)
- Zhili Jin
Institutions
- Capital Medical University (CN)
- Hunan Provincial Center for Disease Control and Prevention (CN)
- Hospital of Hebei Province (CN)
- Shanghai CASB Biotechnology (China) (CN)
- CanSino (China) (CN)
- Beijing Friendship Hospital (CN)
Publication Details
- Journal
- BMC Infectious Diseases
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1186/s12879-025-12053-4
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Key Research and Development Program of China